- Home
- APLM vs GIPR Comparison
APLM vs GIPR Comparison
Compare APLM & GIPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLM
- GIPR
- Stock Information
- Founded
- APLM 2016
- GIPR 2015
- Country
- APLM United States
- GIPR United States
- Employees
- APLM N/A
- GIPR N/A
- Industry
- APLM Blank Checks
- GIPR Real Estate Investment Trusts
- Sector
- APLM Finance
- GIPR Real Estate
- Exchange
- APLM Nasdaq
- GIPR Nasdaq
- Market Cap
- APLM 15.6M
- GIPR 9.7M
- IPO Year
- APLM N/A
- GIPR 2021
- Fundamental
- Price
- APLM $9.75
- GIPR $1.78
- Analyst Decision
- APLM Strong Buy
- GIPR Hold
- Analyst Count
- APLM 2
- GIPR 1
- Target Price
- APLM $425.00
- GIPR N/A
- AVG Volume (30 Days)
- APLM 102.2K
- GIPR 21.0K
- Earning Date
- APLM 02-15-2025
- GIPR 11-15-2024
- Dividend Yield
- APLM N/A
- GIPR 13.15%
- EPS Growth
- APLM N/A
- GIPR N/A
- EPS
- APLM N/A
- GIPR N/A
- Revenue
- APLM $2,101,000.00
- GIPR $10,215,225.00
- Revenue This Year
- APLM N/A
- GIPR N/A
- Revenue Next Year
- APLM N/A
- GIPR $1.14
- P/E Ratio
- APLM N/A
- GIPR N/A
- Revenue Growth
- APLM 70.54
- GIPR 72.92
- 52 Week Low
- APLM $6.50
- GIPR $1.72
- 52 Week High
- APLM $105.00
- GIPR $4.64
- Technical
- Relative Strength Index (RSI)
- APLM 50.39
- GIPR 42.47
- Support Level
- APLM $7.23
- GIPR $1.75
- Resistance Level
- APLM $8.88
- GIPR $1.85
- Average True Range (ATR)
- APLM 1.37
- GIPR 0.08
- MACD
- APLM 0.21
- GIPR -0.01
- Stochastic Oscillator
- APLM 57.91
- GIPR 12.00
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
About GIPR Generation Income Properties Inc.
Generation Income Properties Inc is an internally managed real estate investment company focused on acquiring and managing income-producing retail, office and industrial properties net leased to high-quality tenants in major markets throughout the United States. Its key source of revenue is the rental income. The company holds properties in Alabama, Arizona, Colorado, the District of Columbia, Florida, Illinois, North Carolina and Virginia.